Single and Multiple Ascending Dose Study With EP395

• Sponsor: EpiEndo Pharmaceuticals (Industry)
• Overall Status: Completed
• CT.gov ID: NCT04819854
• Collaborator: (none)
• Enrollment: 78
• Location: 1
• Arms: 2
• Actual Duration (Months): 11.5
• Patients Per Site Per Month: 6.8

Study Details

Study Description

Brief Summary

This is a study to asses the safety and tolerability of single and multiple ascending doses of EP395, administered by oral capsules, in healthy subjects with the aim to determine the safe dose range of EP395 for further clinical development

Condition or Disease	Intervention/Treatment	Phase
Adult ALL	Drug: EP395; Drug: Placebo	Phase 1

Detailed Description

This is a study to asses the safety and tolerability of single and multiple ascending doses of EP395, administered by oral capsules, in healthy subjects with the aim to determine the safe dose range of EP395 for further clinical development. The study consists of two parts, part A where single-ascending doses will be assessed and part B where multiple-ascending doses will be assessed. The primary objective being safety and tolerability as well as the pharmacokinetic properties of EP395.

Study Design

• Study Type: Interventional
• Actual Enrollment: 78 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Intervention Model Description: Single and multiple ascending dosesSingle and multiple ascending doses
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Masking Description: Double-blinded, placebo-controlled
• Primary Purpose: Treatment
• Official Title: A First-in Man, Phase I Study Investigating the Safety and Tolerability of EP395 in Healthy Volunteers
• Actual Study Start Date: Apr 5, 2021
• Actual Primary Completion Date: Mar 22, 2022
• Actual Study Completion Date: Mar 22, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: EP395 EP395 in ascending doses. Orally, once daily.	Drug: EP395; capsule for oral treatment
Placebo Comparator: Placebo Placebo, weight matched in ascending doses. Orally, once daily.	Drug: Placebo; capsule for oral treatment

Outcome Measures

Primary Outcome Measures

1. To assess the safety of EP395 [from baseline to day 7 and day 42]

   Adverse Events

2. To assess the effect of EP395 on ECG [from baseline to day 7 and day 42]

   QT intervals

3. To assess the effect of EP395 on temperature [from baseline to day 7 and day 42]

   Temperature

4. To assess the effect of EP395 on blood pressure [from baseline to day 7 and day 42]

   Blood pressure

5. To assess the effect of EP395 on pulse [from baseline to day 7 and day 42]

   Pulse

6. To assess the effect of EP395 on hearing [from baseline to day 7 and day 42]

   Audiometry

Secondary Outcome Measures

1. To assess the Cmax of EP395 in plasma and blood [from baseline to day 7 and day 42]

   Maximum Plasma Concentration [Cmax]

2. To assess the tmax of EP395 in plasma and blood [from baseline to day 7 and day 42]

   Time to reach Cmax (Tmax)

3. To assess the t½ of EP395 in plasma and blood [from baseline to day 7 and day 42]

   Time to half-life (t½)

4. To assess the AUC of EP395 in plasma and blood [from baseline to day 7 and day 42]

   Area Under the Curve (AUC)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. Subject's written informed consent obtained prior to any study-related procedures.

2. Able to understand and comply with the requirements of the study, as judged by the investigator or designee.

3. Men and women between 18-65 years inclusive

4. Female subjects must either be of non-childbearing potential or if of childbearing potential, must not be pregnant or breast feeding and use a highly effective birth control method during treatment and for 90 days following last dose

5. Male subjects must use highly effective contraception during treatment and for 90 days following last administered dose

6. Subject must agree not to donate semen or ova/oocytes during the study and for 90 days after the last dose of IMP

7. Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2.

8. Subjects with normal hearing

9. Subjects must be in good health at the time of screening

Exclusion Criteria:

1. History or presence of any clinically relevant acute or chronic medical or psychiatric condition that could interfere with the subject's safety.

2. History or presence of vestibular disorder including vertigo, dizziness or other auditory impairment as judged by the investigator or designee.

3. After 10 minutes supine rest at the time of screening or prior to dosing, any vital signs values outside the following ranges:

• Systolic blood pressure <90 or >150 mmHg, or

• Diastolic blood pressure <50 or >95 mmHg, or

• Pulse <40 or >90 bpm

1. Any clinically significant abnormalities in resting ECG at the time of screening or pre-dose Day 1 including prolonged QTcF (>450 ms for males; >470 ms for females) and cardiac arrhythmias, as judged by the Investigator or designee.

2. Clinically significant abnormalities in renal function:

• serum creatinine >ULN

• eGFR <60 mL/min or ≥ 60mL/min with evidence of any kidney dysfunction (e.g. proteinuria, or clinical findings as judged by the investigator)

1. Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP (Day 1).

2. Malignancy within the past five years with the exception of in situ removal of basal cell carcinoma or resected benign colonic polyps.

3. Any planned major surgery within the duration of the study.

4. History of latent or active tuberculosis or a positive Quantiferon test at screening.

5. Females who are pregnant, breast feeding or plan to be pregnant during the study period or 90 days after.

6. Female subjects with a positive serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) at screening and within 24 h prior to the first administration of IMP.

7. Positive serum hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus (HIV) 1 and/or 2 antibodies at screening.

8. Positive PCR test for active COVID -19 tested within seven days prior to administration of the IMP on Day 1.

9. History of any drug and/or alcohol abuse in the past two years prior to screening.

10. Regular alcohol consumption in males >21 units per week and females >14 units per week.

11. Positive urine drugs of abuse test and/or alcohol breath test at screening or on admission to the unit prior to administration of the IMP on Day -1 that cannot be accounted for by concomitant medication in the opinion of the Investigator or designee.

12. Current or previous use of tobacco, nicotine products or e-cigarettes in the past six months.

13. Smoking history of > 5 pack years.

14. Positive urine cotinine test at screening or Day -1.

15. Use of any prescribed or non-prescribed medication including analgesics, herbal remedies, vitamins and minerals within two weeks prior to the (first) administration of IMP, except those listed below, at the discretion of the Investigator or designee:

• hormone replacement therapy (HRT)

• hormonal contraception

• occasional intake of paracetamol (maximum 2000 mg/day for 3 consecutive days)

• nasal decongestants without cortisone for a maximum of 10 days

• antihistamines for a maximum of 10 days

• anticholinergics for a maximum of 10 days

1. Use of antacids, PPIs or any medication that changes gastric pH within two weeks prior to the first administration of IMP (Day 1).

2. Use of macrolide antibiotics within two weeks prior to the first administration of IMP (Day 1)

3. Subjects who have received a live vaccine in the 28 days prior to Day 1.

4. Plasma donation within one month of screening or blood donation (or corresponding blood loss) ≥400mL during the three months prior to screening.

5. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or designee at screen.

6. Subject has dietary restrictions incompatible with the diet that can be provided by the study site, in the opinion of the Investigator or is unwilling to refrain from consuming restricted foods and beverages during the study

7. Regular excessive caffeine consumption defined by a daily intake of >5 cups of caffeine containing beverages.

8. Known history of intolerance or hypersensitivity to macrolides, EP395 or to any other component of the formulation.

9. Known history of intolerance to lactose.

10. Clinically significant serious adverse reaction, allergy or serious hypersensitivity, including to any drug or food, as judged by the Investigator or designee.

11. Involvement in the planning and conduct of the study (applies to all EpiEndo, CRO or investigational site staff).

12. Participation in another clinical study with an experimental drug within three months or 5 half-lives, whichever is shorter, before the administration of IMP.

13. Considered unsuitable for entry into the study in any other way at the discretion of the principal investigator or designee, e.g. investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The Medicines Evaluation Unit (MEU) Ltd.	Manchester		United Kingdom	M23 9QZ

Sponsors and Collaborators

• EpiEndo Pharmaceuticals

Investigators

• Principal Investigator: Dave Singh, Prof., The Medicines Evaluation Unit (MEU) Ltd.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: EpiEndo Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT04819854
• Other Study ID Numbers: EP395-001
• First Posted: Mar 29, 2021
• Last Update Posted: Mar 24, 2022
• Last Verified: Mar 1, 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Mar 24, 2022